Biotech week ahead highlights Novo Nordisk, SLS009, FDA hearing
Preview of a catalyst-heavy biotech week, including Novo Nordisk’s strategy and pipeline update, Sellas Life Sciences’ SLS009 presentations, and a Senate hearing on FDA leadership, plus at least two clinical updates guided for the third quarter.